

REMARKS

The present application is directed to specific fragments of the STEAP1 protein, claims to which were allowed in the parent application herein. A terminal disclaimer with respect to the parent application is enclosed.

Support for the peptides of claim 40 is found as follows: support for the peptide at positions 14-28 of SEQ ID NO: 2 is found on page 41 of the specification at line 19. This peptide was used to generate antibodies immunospecific for STEAP1. Support for the remaining three peptides is found on page 20, lines 19-22 which states that preferred antibodies useful for cancer therapy are those that react with an epitope and extracellular region of the STEAP protein in combination with Figure 1B which shows positions 92-113; 185-218; and 277-291 as extracellular regions. This is further spelled out on page 22, lines 35-37.

The dependent claims parallel those allowed in the parent. No new matter has been added.

It is believed the claims as proposed are in a position for immediate allowance. Consideration of these claims and passage of these claims to issue is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket No. 511582001601.

Respectfully submitted,

Dated: December 6, 2001

By:

Kate H. Murashige
Kate H. Murashige
Registration No. 29,959

Morrison & Foerster LLP
3811 Valley Centre Drive, Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125